InsiderDXBi

LIFEPharma (Life Pharma FZE)

Growth Score40DXBi Rank173Heat Score100

Life Pharma FZE

UAE's only USFDA-approved pharmaceutical manufacturer, part of the VPS Health group.

Founded 2011Private (subsidiary of VPS Health / VPS Healthcare group)Jebel Ali Free Zone, Dubai, UAE (per company site; new manufacturing platform under development at KEZAD, Abu Dhabi), Dubai501-1000 employeeslifepharmafze.com
Prospect profilepharmaceutical manufacturingUSFDA approvedVPS HealthJebel Ali Free ZoneKEZADgene therapy
Visit Website

Media

Preview imagery published alongside each story, linking back to the original.

Overview

LIFEPharma (Life Pharma FZE) is a Dubai (Jebel Ali Free Zone)-based pharmaceutical manufacturer established in 2011, and describes itself as the only USFDA-approved pharmaceutical manufacturing plant in the UAE, producing tablets, capsules and liquid formulations for domestic and export markets. The company is part of the VPS Health group (VPS Healthcare), the UAE-headquartered integrated healthcare group founded by Dr. Shamsheer Vayalil, which operates hospitals and healthcare businesses across the UAE, Oman, Saudi Arabia and India. In 2026 LIFEPharma signed an MoU with AD Ports Group for a roughly Dh700 million (~US$190 million) pharmaceutical manufacturing platform at Khalifa Economic Zones Abu Dhabi (KEZAD), covering vaccine fill-and-finish, oncology, and advanced injectables/biologics production, and separately launched a ~AED 100 million gene-therapy initiative (spin-off entity EQUIGENE Therapeutics) targeting hemophilia, thalassemia and sickle cell disease.
40

Growth Score

Steady

100

Heat Score

Trending up

Details

Operating Status
Active
Company Type
Private (subsidiary of VPS Health / VPS Healthcare group)
Headquarters
Jebel Ali Free Zone, Dubai, UAE (per company site; new manufacturing platform under development at KEZAD, Abu Dhabi)
Founded
2011
Company Size
501-1000 employees
Revenue
$25M-$50M (per Datanyze third-party estimate; unverified against primary source)
Founders
Prof. Alok Srivastava

Products & Services

Avilife (Favipiravir 200mg)

Antiviral tablet, developed for COVID-19 treatment

Antijoin

Anti-adhesion solution (Hydroxyethyl starch + Sodium hyaluronate) used in surgery

Clopimet (Clopidogrel 75mg)

Anticoagulant/antiplatelet tablet

Gastrex (Simethicone 42mg)

Antiflatulent

Loralife (Loratadine 10mg)

Antihistamine

Telife (Fexofenadine HCl)

Antihistamine

Lipira (Atorvastatin)

Antihyperlipidemic (cholesterol-lowering) tablet

Rosulife (Rosuvastatin)

Antihyperlipidemic (cholesterol-lowering) tablet

Equigene Therapeutics

LIFEPharma-launched gene/cell therapy biotech platform targeting hemophilia, thalassemia and sickle cell disease

People

Technology

No technology or web presence data on file yet.

Financials

Funding rounds

Projects

Partnership / Major Project LaunchAnnounced

LIFEPharma - AD Ports Group Kezad Manufacturing Platform

LIFEPharma signed an MOU with AD Ports Group during Make it in the Emirates 2026 to build a Dh700m ($191m) advanced pharmaceutical manufacturing platform at Khalifa Economic Zones Abu Dhabi (Kezad), comprising a Dh300m vaccine fill-and-finish facility, Dh200m oncology manufacturing, and Dh200m for peptides/biologics/injectables. Projected to add ~Dh2bn to GDP and create 1,000+ jobs. Signed by Capt. Mohamed Juma Al Shamisi (AD Ports Group CEO), Dr. Shamsheer Vayalil and Omran Al Khoori (VPS Health) and Abdullah Al Hameli (AD Ports).

$191M

May 5, 2026

Partnership / FinancingAnnounced

LIFEPharma - Ajman Bank Strategic Financing Agreement

Ajman Bank signed a strategic financing agreement with LIFEPharma at Make it in the Emirates 2026 to support LIFEPharma's expansion roadmap, including advanced manufacturing, complex therapies (injectables/specialized formulations), IP acquisition, product development, and technology adoption. Specific financing amount was not disclosed in reporting.

May 5, 2026

Project Launch / Corporate SpinoffAnnounced

Equigene Therapeutics Gene Therapy Initiative Launch

LIFEPharma launched Equigene Therapeutics, an AED100m ($27.2m) region-first cell-and-gene-therapy biotech platform targeting rare inherited blood disorders (hemophilia A and B, thalassemia, sickle cell disease), led by hematologist Prof. Alok Srivastava, in partnership with Burjeel Holdings' Center for Research on Rare Blood Disorders (Prof. Khaled Musallam) as part of a UAE-India healthcare corridor collaboration. Targeting a 3-5 year go-to-market timeline.

$27M

May 5, 2026

Contract AwardCompleted

LIFEPharma - Apotex 10-Year Generic Drug Export Agreement

LIFEPharma signed a 10-year deal with Canada's Apotex to manufacture up to 120 million tablets annually of nine generic medications (covering conditions including ALS, Parkinson's, Hepatitis B, seizures, and resistant bacterial infections) for export to Canada, making LIFEPharma the first UAE company to export generics to the North American market. Quoted: Dr. Shamsheer Vayalil (VPS Healthcare) and Jeff Watson (Apotex President & CEO).

Oct 9, 2019

Similar Companies

Official Channels

Where LIFEPharma (Life Pharma FZE) publishes directly. Each link is checked for the correct platform and profile format.

A tick means the link resolves to a valid company profile URL on that platform. It does not confirm the account is operated by LIFEPharma (Life Pharma FZE) — that requires a signal only the platform or the company can give, so DXBi does not claim it.

Press & Announcements

Every item links back to its original source. Announcements are only marked as coming from LIFEPharma (Life Pharma FZE) when the link resolves to the company's own domain.

Loading press coverage…

Signals & News

Insights

Reviews